LBRX
LB Pharmaceuticals Inc Common Stock
NASDAQ: LBRX · HEALTHCARE · BIOTECHNOLOGY
$31.71
+3.66% today
Updated 2026-04-30
Market cap
$912.17M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-3.13
Dividend yield
—
52W range
$13 – $33
Volume
0.3M
LB Pharmaceuticals Inc Common Stock (LBRX) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — |
| Cost of revenue | — | — | — | $321000.00 |
| Gross profit | — | — | — | $-321000.00 |
| Gross margin | — | — | — | — |
| R&D | $1.35M | $7.84M | $51.17M | $16.74M |
| SG&A | $1.46M | $3.53M | $13.66M | $13.66M |
| Operating income | $-2.81M | $-11.38M | $-64.83M | $-30.40M |
| Operating margin | — | — | — | — |
| EBITDA | $-12.19M | $-1.45M | $-63.01M | $-30.08M |
| EBITDA margin | — | — | — | — |
| EBIT | $-12.20M | $-1.45M | $-63.10M | $-30.40M |
| Interest expense | $2.15M | $4.83M | $0.00 | — |
| Income tax | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-14.35M | $-6.28M | $-63.10M | $-25.20M |
| Net income growth (YoY) | — | +56.3% | -905.6% | +60.1% |
| Profit margin | — | — | — | — |